Previous 10 | Next 10 |
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
2024-04-23 17:20:49 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...
2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...
2024-04-21 21:02:00 ET Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization. Pfizer acquired Seagen in 2023 wh...
2024-04-21 20:04:07 ET More on Eli Lilly, Novo Nordisk, etc. Read the full article on Seeking Alpha For further details see: 13 new obesity drugs could hit the market by 2029 amid surging demand
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-18 16:01:51 ET Summary VKTX has reported positive data from a phase 1 trial of the oral formulation of VK2735, showing a placebo-adjusted weight loss of 3.3% at the highest dose at 28 days. There was an absence of plateauing of weight loss at 4 weeks at the higher doses, m...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-20 06:00:00 ET California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributors think they've found bi...
2024-07-19 05:50:00 ET Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candid...
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc...